Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1Phase 2 1

Status

Completed 3Recruiting 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4CNS 2

Conditions

Melanoma 250Carcinoma, Non-Small-Cell Lung 86Carcinoma, Renal Cell 62Neoplasm Metastasis 53Neoplasms 51Prostatic Neoplasms 35Lung Neoplasms 32Uveal Melanoma 29Pancreatic Neoplasms 28Carcinoma, Hepatocellular 25Brain Neoplasms 24Colorectal Neoplasms 23Sarcoma 22Breast Neoplasms 20Squamous Cell Carcinoma of Head and Neck 18Small Cell Lung Carcinoma 18Kidney Neoplasms 18Skin Neoplasms 17Diabetes Mellitus, Insulin-Dependent, 12 17Carcinoma, Transitional Cell 17Ovarian Neoplasms 15Urinary Bladder Neoplasms 14Triple Negative Breast Neoplasms 14Mesothelioma 13Glioblastoma 13Uterine Cervical Neoplasms 12Recurrence 12Multiple Myeloma 11Lymphoma 11Clear-cell metastatic renal cell carcinoma 11

Interventions

Temozolomide 131Radiotherapy 87Bevacizumab 43Radiation 31Carmustine 29Magnetic Resonance Spectroscopy 22Irinotecan 22Erlotinib Hydrochloride 22Chemotherapy, Adjuvant 20Surgical Procedures, Operative 15O(6)-benzylguanine 15Carboplatin 14Radiotherapy, Intensity-Modulated 13Radiotherapy, Conformal 13sargramostim 12Sirolimus 9Imatinib Mesylate 9Filgrastim 9Drug Therapy 9temsirolimus 8Thalidomide 8Sorafenib 8Radiosurgery 8pembrolizumab 7motexafin gadolinium 7aldesleukin 7Vorinostat 7Procarbazine 7Gene Expression Profiling 7Gefitinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Gliosarcoma × Ipilimumab × Clear all
NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

National Cancer Institute (NCI)

Phase 2/3 Completed
159 enrolled 17 charts
Sarcoma

Gliosarcoma

NCT04817254 2026-04-17

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
47 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT07134842 2026-04-09

WinGlio-ipi

University College, London

Phase 1 Recruiting
16 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT02311920 2023-01-10

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

National Cancer Institute (NCI)

Phase 1 Completed
32 enrolled
Sarcoma

Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡